See also:

BIP study, 2000	TRC2584
	download pdf: bezafibrate | cholesterol lowering intervention for post myocardial infarction

Treatments

Studied treatment	bezafibrate 400 mg/d
Control treatment	placebo
Concomittant treatment	R�gime; colestipol � 165 patients (57 dans le groupe bezafibrate et 107 dans le groupe contr�le)

Patients

Patients	patients with a previous myocardial infarction or stable angina, total cholesterol of 180 to 250 mg/dL, HDL-C < or =45 mg/dL, triglycerides < or =300 mg/dL, and low-density lipoprotein cholesterol < or =180 mg/dL
Inclusion criteria	age of 45 to 74 years, history of MI >=6 months but <5 years before enrollment into the study and/or stable angina pectoris confirmed by coronary angiography, and/or radionuclear studies or standard exercise tests; serum total cholesterol between 180 to 250 mg/dL, LDL-C <=180 mg/dL (>=160 mg/dL for patients ,50 years), HDL-C <=45 mg/dL, and triglycerides <=300 mg/dL
Exclusion criteria	insulin-dependent diabetes mellitus, severe heart failure, unstable angina pectoris, hepatic or renal failure, known sensitivity to bezafibrate, or current use of lipid-modifying drugs
Baseline characteristics	Age (mean), yrs 60  Women (%) 9  prior MI or CHD (%) 100  Total cholesterol (mmol/l) 5.5 mmol/L  LDL (mmol/l) 3.84 mmol/L  HDL (mmol/l) 0.89 mmol/L  Triglycerides (mg/dl) 145  Diabetes(%) 10%  BMI (kg/m2) 26.7  Stroke history 1%  History of hypertension (%) 32%

Method and design

Randomized effectives	1548 / 1542 (studied vs. control)
Design	Parallel groups
Blinding	double blind
Follow-up duration	6.2 y
Number of centre	multicentre
Geographic area	Israel
Hypothesis	Superiority
Primary endpoint	IDM fatal ou non fatal ou d�c�s coronarien

Results

Endpoint Studied treat.
n/N Control treat.
n/N Graph RR [95% CI]

Coronary event

211 / 1548
232 / 1542
0,91 [0,76;1,08]

All cause death

161 / 1548
152 / 1542
1,06 [0,86;1,30]

Coronary death

61 / 1548
60 / 1542
1,01 [0,71;1,44]

stroke (fatal and non fatal)

72 / 1548
77 / 1542
0,93 [0,68;1,27]

MACE

522 / 1548
559 / 1542
0,93 [0,84;1,02]

Non fatal MI

150 / 1548
172 / 1542
0,87 [0,71;1,07]

Coronary death and non fatal MI

211 / 1548
232 / 1542
0,91 [0,76;1,08]

cardiac death

61 / 1548
60 / 1542
1,01 [0,71;1,44]

non cardiovascular death

66 / 1548
64 / 1542
1,03 [0,73;1,44] 0 2 1.0

Relative risks
Endpoint	Events (%)		Relative Risk	95% CI	Endpoint definition in the trial	Ref
	Studied treat.	Control treat.
Coronary event	211 / 1548 (13,6%)	232 / 1542 (15,0%)	0,91	[0,76;1,08]		0
All cause death	161 / 1548 (10,4%)	152 / 1542 (9,9%)	1,06	[0,86;1,30]
Coronary death	61 / 1548 (3,9%)	60 / 1542 (3,9%)	1,01	[0,71;1,44]
stroke (fatal and non fatal)	72 / 1548 (4,7%)	77 / 1542 (5,0%)	0,93	[0,68;1,27]
MACE	522 / 1548 (33,7%)	559 / 1542 (36,3%)	0,93	[0,84;1,02]	cardiac events + revasc	1750
Non fatal MI	150 / 1548 (9,7%)	172 / 1542 (11,2%)	0,87	[0,71;1,07]
Coronary death and non fatal MI	211 / 1548 (13,6%)	232 / 1542 (15,0%)	0,91	[0,76;1,08]		1750
cardiac death	61 / 1548 (3,9%)	60 / 1542 (3,9%)	1,01	[0,71;1,44]
non cardiovascular death	66 / 1548 (4,3%)	64 / 1542 (4,2%)	1,03	[0,73;1,44]	noncardiac death	1750
The primary endpoint (if exists) appears in blod characters
Reference(s) used for data extraction: 0: 1750: ,Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study.Circulation 2000; 102:21-7

Endpoint	studied treat.	control treat.	mean diff

Absolute risk reduction (for a follow-up of 6.2 y)
Endpoint	Events rate		Absolute risk reduction (ARR)
	Studied treat.	Control treat.
Coronary event	13,63%	15,05%	-1,41%
All cause death	10,40%	9,86%	0,54%
Coronary death	3,94%	3,89%	0,05%
stroke (fatal and non fatal)	4,65%	4,99%	-0,34%
MACE	33,72%	36,25%	-2,53%
Non fatal MI	9,69%	11,15%	-1,46%
Coronary death and non fatal MI	13,63%	15,05%	-1,41%
cardiac death	3,94%	3,89%	0,05%
non cardiovascular death	4,26%	4,15%	0,11%

Meta-analysis of all similar trials:

cholesterol lowering intervention in cardiovascular prevention for all chronical situations

cholesterol lowering intervention in post myocardial infarction for all type of patients

HDL increasing drugs in cardiovascular prevention for all type of patients

Reference(s)

TrialResults-center ID	TRC2584
Trials register #	NA

• ,. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study.. Circulation 2000; 102:21-7
  Pubmed | Hubmed | Fulltext
• Goldenberg I, Boyko V, Tennenbaum A, Tanne D, Behar S, Guetta V. Long-term benefit of high-density lipoprotein cholesterol-raising therapy with bezafibrate: 16-year mortality follow-up of the bezafibrate infarction prevention trial.. Arch Intern Med 2009;169:508-14
  Pubmed | Hubmed | Fulltext

(c) 2004-2016 TrialResults-center - All Rights Reserved